期刊文献+

重度、极重度COPD急性加重期合并多器官功能障碍226例临床研究 被引量:2

Clinical Study of 226 Cases of Severe or Very Severe Chronic Obstructive Pulmonary Disease Exacerbation Combining with Multiple Organ Dysfunction Syndrome
原文传递
导出
摘要 目的:探讨重度、极重度COPD急性加重期合并多MODS临床特征和预后有关的危险因素。方法:回顾分析1999~2009年因重度、极重度COPD急性期合并多器官功能障碍而住院的患者临床资料。结果:本研究共纳入226例患者,平均年龄为69.3±5.2岁。呼吸系统功能障碍发生率最高,有200例。其次是心血管功能障碍和中枢神经功能障碍,各102例。患者的病死率随着器官功能障碍的数目增加而增加。结论:治疗重度、极重度COPD急性加重时,在常规治疗基础的同时防治MODS是降低患者病死率的关键。 Objective:To analyze the clinical characters and risk factors that relevant to prognosis of severe or very severe chronic obstructive pulmonary disease(COPD)exacerbation combining with multiple organ dysfunction syndrome(MODS).Methods:The clinical data of patients who was admitted to hospital for exacerbation of severe or very severe COPD combing with MODS in 1999 to 2009 were retrospective analyzed.Results:226 cases were analyzed in this study,the mean age of patients was 69.3±5.2.The incidence of respiratory system dysfunction was highest,which was 200 cases,and followed by the incidence of cardiovascular dysfunction and central nervous system dysfunction,which was 102 respectively.The mortality of these patients increased with the increasing number of organ dysfunction.Conclusion:Prevent and te at MODS on the basis of conventional treatment of severe or very severe COPD exacerbation is the key factor that could reduce mortality of these patients.
出处 《华西医学》 CAS 2009年第10期2588-2590,共3页 West China Medical Journal
关键词 慢性阻塞性肺疾病 多器官功能障碍综合征 预后 chronic obstructive pulmonary disease COPD multiple organ dysfunction syndrome MODS prognosis
  • 相关文献

参考文献12

二级参考文献17

共引文献1971

同被引文献25

  • 1曹振英,Tan Wan Cheng,Ng Tze Pin.影响慢性阻塞性肺病急性加重患者生活质量的危险因素[J].上海第二医科大学学报,2005,25(7):722-726. 被引量:10
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 3Donaldson GC, Wedzicha JA. COPD exacerbations.l: Epidemiology[J]. Thorax, 2006, 61(2): 164-168.
  • 4Fromer L, Barnes T, Garvey C, et al. Innovations to achieve excellence in COPD diagnosis and treatment in primary care[J]. Postgrad Med, 2010, 122(5): 150-164.
  • 5Han MK, Martinez FJ. Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease[J]. Proc Am Thorac Soc, 2011, 8(4) : 356-362.
  • 6O'Donnell DE, Flfige T, Gerken F, et al. Effects of tiotropium onlung hyperinflation dyspnoea and exercise tolerance in COPD[J]. Eur Respir J, 2004, 23(6): 832-840.
  • 7Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease[J]. Clin Ther, 2005, 27(4): 377-392.
  • 8Tashkin DP, Celli B, Senn S, et al. A 4 - year trial of tiotropium in chronic obstructive pulmonary disease[J]. N Engl J Med, 2008, 359(15) : 1543-1554.
  • 9van Noord JA, Smeets J J, Custers FL, et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease[J]. Eur Respir J, 2002, 19(4): 639-644.
  • 10Vogelmeier C, Hederer B, Glaab T, et al. Totropium versus Salmeterol for the prevention of exacerbations of COPD[J]. N Engl J Med, 2011,364(12): 1093-1103.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部